Nanotherapy for Duchenne muscular dystrophy.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

• Publication date

  2018-03-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1002/wnan.1472PMID 28398005PMCID PMC5636659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poly(ester amine) Composed of Polyethylenimine and Pluronic Enhance Delivery of Antisense Oligonucleotides In Vitro and in Dystrophic mdx Mice

  2016cited by this paper
• Dystrophin gene replacement and gene repair therapy for Duchenne muscular dystrophy in 2016.

  2016cited by this paper
• 499. Intravenous Delivery of a Novel Micro-Dystrophin Vector Prevented Muscle Deterioration in Young Adult Canine Duchenne Muscular Dystrophy Dogs

  2016cited by this paper
• Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

  2016cited by this paper
• Dystrophin-Deficient Cardiomyopathy.

  2016cited by this paper
• CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.

  2016cited by this paper
• Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview

  2016cited by this paper
• Systemic delivery of adeno-associated viral vectors.

  2016cited by this paper
• Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations

  2016cited by this paper
• In vivo tissue-tropism of adeno-associated viral vectors.

  2016cited by this paper
• Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors.

  2016cited by this paper
• Progress and prospects of gene therapy clinical trials for the muscular dystrophies.

  2016cited by this paper
• Noncoding RNAs and Duchenne muscular dystrophy.

  2016cited by this paper
• In vivo gene editing in dystrophic mouse muscle and muscle stem cells

  2016cited by this paper
• Applications of CRISPR technologies in research and beyond

  2016cited by this paper
• In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

  2016cited by this paper
• Lentiviral vectors, two decades later

  2016cited by this paper
• Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study

  2015cited by this paper
• Delivery of therapeutic oligonucleotides with cell penetrating peptides☆

  2015cited by this paper
• Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.

  2015cited by this paper
• Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice

  2015cited by this paper
• AAV's Golden Jubilee.

  2015cited by this paper
• Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.

  2015cited by this paper
• Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers

  2015cited by this paper
• TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy.

  2015cited by this paper
• Prevalence of Duchenne and Becker Muscular Dystrophies in the United States

  2015cited by this paper
• European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.

  2015cited by this paper
• Tris[2-(Acryloyloxy)Ethyl]Isocyanurate Cross-Linked PolyethylenimineEnhanced Exon-Skipping of Antisense 2′-Omethyl PhosphorothioateOligonucleotide in vitro and in vivo

  2015cited by this paper
• AAV ANCESTRAL RECONSTRUCTION LIBRARY ENABLES SELECTION OF BROADLY INFECTIOUS VIRAL VARIANTS

  2015cited by this paper
• A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

  2015cited by this paper
• In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector.

  2015cited by this paper
• Contemporary Cardiac Issues in Duchenne Muscular Dystrophy

  2015cited by this paper
• Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy

  2015cited by this paper
• Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice

  2015cited by this paper
• AAV-8 Is More Efficient than AAV-9 in Transducing Neonatal Dog Heart

  2015cited by this paper
• Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy

  2015cited by this paper
• Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice

  2015cited by this paper
• Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies

  2015cited by this paper
• Duchenne Muscular Dystrophy Gene Therapy in the Canine Model

  2015cited by this paper
• Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction and Is Associated With Age and Steroid Treatment Duration in Duchenne Muscular Dystrophy

  2015cited by this paper
• Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test

  2015cited by this paper
• Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy

  2014cited by this paper
• Exosomes as Critical Agents of Cardiac Regeneration Triggered by Cell Therapy

  2014cited by this paper
• Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

  2014cited by this paper
• Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle

  2014cited by this paper
• Ataluren treatment of patients with nonsense mutation dystrophinopathy

  2014cited by this paper
• Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, -6, and -9 in neonatal dogs

  2014cited by this paper
• Development and applications of CRISPR-Cas9 for genome engineering.

  2014cited by this paper
• Parvovirus glycan interactions.

  2014cited by this paper
• Peptide Conjugation of 2′-O-methyl Phosphorothioate Antisense Oligonucleotides Enhances Cardiac Uptake and Exon Skipping in mdx Mice

  2014cited by this paper
• Engineering adeno-associated viruses for clinical gene therapy

  2014cited by this paper
• Nanoparticle Delivery of Antisense Oligonucleotides and Their Application in the Exon Skipping Strategy for Duchenne Muscular Dystrophy

  2014cited by this paper
• Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy

  2014cited by this paper
• Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors

  2014cited by this paper
• High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics

  2014cited by this paper
• Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.

  2014cited by this paper
• A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy

  2014cited by this paper
• Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy.

  2014cited by this paper
• AAV-Mediated Gene Therapy for Research and Therapeutic Purposes.

  2014cited by this paper
• MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.

  2014cited by this paper
• Triple Trans-Splicing Adeno-Associated Virus Vectors Capable of Transferring the Coding Sequence for Full-Length Dystrophin Protein into Dystrophic Mice

  2014cited by this paper
• Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function

  2014cited by this paper
• Adeno-associated virus structural biology as a tool in vector development.

  2013cited by this paper
• Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals.

  2013cited by this paper
• Steroids in Duchenne muscular dystrophy.

  2013cited by this paper
• Liposomal drug delivery systems: from concept to clinical applications.

  2013cited by this paper
• Biodistribution and Molecular Studies on Orally Administered Nanoparticle-AON Complexes Encapsulated with Alginate Aiming at Inducing Dystrophin Rescue in mdx Mice

  2013cited by this paper
• Sarcospan: a small protein with large potential for Duchenne muscular dystrophy

  2013cited by this paper
• Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.

  2013cited by this paper
• Long-Term Robust Myocardial Transduction of the Dog Heart from a Peripheral Vein by Adeno-Associated Virus Serotype-8

  2013cited by this paper
• Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells

  2013cited by this paper
• Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

  2013cited by this paper
• A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays

  2013cited by this paper
• Pluronic–PEI copolymers enhance exon-skipping of 2′-O-methyl phosphorothioate oligonucleotide in cell culture and dystrophic mdx mice

  2013cited by this paper
• Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy.

  2013cited by this paper
• Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury.

  2013cited by this paper
• Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy

  2013cited by this paper
• Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy

  2013cited by this paper
• Functional muscle ischemia in Duchenne and Becker muscular dystrophy

  2013cited by this paper
• AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice.

  2013cited by this paper
• Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping.

  2012cited by this paper
• Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy.

  2012cited by this paper
• microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice.

  2012cited by this paper
• Biodegradable polymersomes as carriers and release systems for paclitaxel using Oregon Green® 488 labeled paclitaxel as a model compound.

  2012cited by this paper
• A Simplified Immune Suppression Scheme Leads to Persistent Micro-dystrophin Expression in Duchenne Muscular Dystrophy Dogs

  2012cited by this paper
• Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.

  2012cited by this paper
• Molecular dissection of dystrophin identifies the docking site for nNOS

  2012cited by this paper
• Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice

  2012cited by this paper
• Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

  2012cited by this paper
• Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.

  2012cited by this paper
• Novel Mini–Dystrophin Gene Dual Adeno-Associated Virus Vectors Restore Neuronal Nitric Oxide Synthase Expression at the Sarcolemma

  2012cited by this paper
• Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery

  2012cited by this paper
• Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment

  2012cited by this paper
• Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

  2012cited by this paper
• Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping

  2012cited by this paper
• Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs

  2012cited by this paper
• AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.

  2012cited by this paper
• Humoral Immunity to AAV-6, 8, and 9 in Normal and Dystrophic Dogs

  2012cited by this paper
• Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

  2012cited by this paper
• Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA

  2012cited by this paper

• Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice

  2025influential citation
• Scientific and Technological Prospecting on Polymeric Particles Containing Extracellular Matrix Peptides for the Treatment of Duchenne Muscular Dystrophy.

  2025cites this paper
• Nanomedicine Therapies for Pediatric Diseases

  2024cites this paper
• Non-viral delivery of nucleic acid for treatment of rare diseases of the muscle

  2024cites this paper
• The future of rare autonomic disease research

  2023cites this paper
• Nanoparticles systemically biodistribute to regenerating skeletal muscle in DMD

  2023cites this paper
• Nanomedicine and Its Potential Therapeutic and Diagnostic Applications in Human Pathologies

  2022cites this paper
• Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations

  2022cites this paper
• Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies

  2021cites this paper
• Role of the HSP70 Co-Chaperone SIL1 in Health and Disease

  2021cites this paper
• The era of gene therapy: from preclinical development to clinical application.

  2021cites this paper
• MiRNAs and Muscle Regeneration: Therapeutic Targets in Duchenne Muscular Dystrophy

  2021cites this paper
• Duchenne Muscular Dystrophy Animal Models

  2021cites this paper
• Scaffold biomaterials and nano-based therapeutic strategies for skeletal muscle regeneration.

  2021cites this paper
• Peptide-Functionalized Dendrimer Nanocarriers for Targeted Microdystrophin Gene Delivery

  2021cites this paper
• In Vivo Genome Engineering for the Treatment of Muscular Dystrophies

  2020cites this paper
• Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine

  2020cites this paper
• Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy

  2020cites this paper
• Advance in Drug Delivery for Ageing Skeletal Muscle

  2020cites this paper
• Gene Therapy Leaves a Vicious Cycle

  2019cites this paper
• Hexose Potentiates Peptide-Conjugated Morpholino Oligomer Efficacy in Cardiac Muscles of Dystrophic Mice in an Age-Dependent Manner

  2019cites this paper
• Sarcolipin Knockdown Therapy for Duchenne Muscular Dystrophy

  2019cites this paper
• Protein-anchoring therapy to target extracellular matrix proteins to their physiological destinations.

  2018cites this paper
• Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

  2018cites this paper
• Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy

  2018cites this paper
• Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials.

  2018cites this paper
• The use of magnetic resonance imaging and proton spectroscopy to identify critical tissues in dogs with Duchenne Muscular Dystrophy for future assessment of therapeutic intervention : a pilot study

  2018cites this paper
• Congenital Heart Disease Gene Identification by Whole Exome Sequencing

  2017cites this paper
• In Vivo Electroporation of Plasmid DNA into the Skeletal Muscle of Dystrophic Mouse Models.

  year unknowncites this paper